Citius Oncology (NASDAQ:CTOR) Stock Price Down 5.6% – Time to Sell?

Citius Oncology, Inc. (NASDAQ:CTOR) was down 5.6% on Wednesday. The stock traded as low as $0.9850 and last traded at $1.01. 55,828 shares traded hands during trading, a decline of 39% from the average daily volume of 90,829 shares. The stock had previously closed at $1.07.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Citius Oncology Stock Performance

The stock’s 50-day simple moving average is $0.78 and its 200 day simple moving average is $0.77. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.34 and a current ratio of 0.73. The company has a market capitalization of $97.63 million, a PE ratio of -2.23 and a beta of 3.52.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $2.50 million.

Institutional Trading of Citius Oncology

An institutional investor recently raised its stake in Citius Oncology stock. IFP Advisors Inc raised its holdings in shares of Citius Oncology, Inc. (NASDAQ:CTOR) by 163.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 87,424 shares of the company’s stock after acquiring an additional 54,209 shares during the quarter. IFP Advisors Inc owned approximately 0.10% of Citius Oncology worth $87,000 as of its most recent filing with the SEC. 70.52% of the stock is owned by institutional investors.

About Citius Oncology

Citius Oncology, Inc (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious medical conditions. The company was established as an oncology-focused subsidiary of Citius Pharmaceuticals and operates primarily in the United States.

Its lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.